WASHINGTON — President Trump often brags that the “most-favored nation” deals he struck with drugmakers have set the country on a new path to no longer paying more than its fair share for prescription drug costs. But many details of the agreements haven’t been released by the administration and the companies, including their duration.
Now STAT has learned from Securities and Exchange Commission filings that, at least for some of the companies, those deals last three years.
The agreements vary by each of the 16 companies that have struck them, but there are several commonalities.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
